Manish Wani, Swati Jagdale, Pawan Khanna, Ravindra Gholap, Akshay Baheti
Manish Wani1*, Swati Jagdale2, Pawan Khanna3, Ravindra Gholap1, Akshay Baheti2
1MAEER’s Maharashtra Institute of Pharmacy, Kothrud, Pune, Maharashtra, India.
2Faculty of Pharmacy, MIT World Peace University (Former MAEER’s Maharashtra Institute of Pharmacy) Kothrud, Pune, Maharashtra, India.
3Department of Applied Chemistry, Defence Institute of Advanced Technology (DIAT), Girinagar, Pune-411025, Maharashtra India.
Volume - 13,
Issue - 8,
Year - 2020
Objective: In situ gels are systems which are applied as solutions or suspensions and are capable of undergoing rapid sol-to-gel transformation by external stimulus. In situ gels overcome the shortcoming of eye drops like poor bioavailability and poor therapeutic response due to rapid dilution on instillation and wash out. Nano particles have shown improved performance of drug delivery system like increased bioavailability, drug targeting, increased stability, prolonged action and most important reduced dosing frequency. The objective of the present study was to synthesize moxifloxacin capped silver nanoparticles having enhanced antimicrobial action and then formulate it into in situ ophthalmic gelling system which will prolong its residence time for better bioavailability. Methods: Moxifloxacin belongs to class of antibiotics called fluoroquinolones which is popularly used as a broad spectrum antibiotic in the treatment of ophthalmic infections like Conjunctivitis, Blepharitis, Keratitis, Endophthalmitis. Silver is a well-known antimicrobial agent. The in situ gel was formulated using Poloxamer 407 which is temperature induced gelling agent and HPMC K4M which is known to increases mucosal adhesivity and enhance viscosity in order to achieve the desired consistency so as to facilitate sustained drug release. The developed formulations were evaluated for clarity, pH measurement, gelling capacity, drug content, isotonicity, microbiological studies, rheological studies and in vitro drug release. Results: Experimental data demonstrated that the nanoparticles were successfully synthesized and in situ gel was successfully formulated with good parameters in terms of clarity, pH measurement, gelling capacity, drug content and isotonicity. In situ gel formulation (F5) showed in vitro sustained release profile with polymer composites Poloxamer 407 and HPMC K4M. In Vivo Bio-distribution studies of Tc99 labeled Ag-Mox NPs by Micro SPECT/CT showed there was significant increase in ocular residence time of in situ gel as compared to Tc99 labeled marketed ophthalmic solution marketed formulation. Conclusion: The developed system can be a promising alternative to the conventional eye drops due to its ability to enhance availability through its prolonged drug release and longer precorneal residence time. In addition, the ease of administration and the expected reduced frequency of administration will result in better patient compliance.
1. Girish K, Asish D. Design, development, and evaluation of an ion-activated ophthalmic in situ gel of moxifloxacin hydrochloride. Asian J Pharm Clin Res 2019;12(3),94-103
Cite this article:
Manish Wani, Swati Jagdale, Pawan Khanna, Ravindra Gholap, Akshay Baheti. Formulation and Evaluation of Ophthalmic In-Situ Gel using Moxifloxacin Coated Silver Nanoparticles. Research J. Pharm. and Tech. 2020; 13(8):3623-3630. doi: 10.5958/0974-360X.2020.00641.1
2. Preethi G, Narendra E. Formulation and evaluation of in situ mucoadhesive ophthalmic hydrogel for sustained delivery of pefloxacin mesylate. International Journal of Pharmacy and Pharmaceutical Sciences. 2015;7(8):345-350.
3. Rathore K, Nema R and Sisodia S. An overview and advancement in ocular drug delivery systems. International Journal of Pharmaceutical Sciences and Research 2010; 1(10):11-23.
4. Anuja K, Rahul J, Pradnya S, Satwashila K. Design and evaluation of modified chitosan based in situ gel for ocular drug delivery. International Journal of Pharmacy and Pharmaceutical Sciences. 2017;9(11):87-91
5. Sandeep S, Vivek P, Ravi T and Vishnu A. Nanoparticle based drug delivery system: Advantages and applications. Indian Journal of Science and Technology 2011; 4(3):177-180
6. Anima N, Shahnaz M. Improved bactericidal property of silver nanoparticles from penicillium pinophilum (mtcc 2192) in a combined form with carbicillin and moxifloxacin. Int J Pharm Pharm Sci;2014:6(2):609-612.
7. Kandarp M, Mihir S. Synthesis of silver nanoparticles by using sodium borohydride as a reducing agent. International Journal of Engineering Research and Technology; 2013:2(3):1-5
8. Muhammad N, Shujaat A, Muhammad R, Ajmal K, Umar F, Ghias U, Bashir A. Moxifloxacin-capped noble metal nanoparticles as potential urease inhibitors. New J. Chem; 2015: 39: 8080-8086
9. Rema B, Raveendran R, Vaidyan A. Synthesis and characterization of Mn2+-doped ZnS nanoparticles 2007; 68(4):679–687
10. Patel N, Thakkar V, Metalia V, Baldaniya L, Gandhi T, Gohel M. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Drug Dev Ind Pharm. 2016:42(9):1406-23
11. Saxena A, Singh R. A review on levofloxacin in situ-gel formulation, Asian J Pharm Clin Res 2015;8(1),37-41
12. Venkatesh M, Purohit K, Pramod T. Development and evaluation of chitosan based thermosensitive in situ gels of pilocarpine. Int J Pharm Pharm Sci;2014:6(2):609-612.
13. Controller of Publication, Indian Pharmacopoeia, Ministry of Health and Family Welfare, Government of India, New Delhi, 2007
14. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001;69:379-88.
15. Paliwal S, Chauhan R, Sharma V, Majumdar D. Entrapment of ketorolac tromethamine in polymeric vehicle for controlled drug delivery. Indian J Pharm Sci, 2009, 71 (6): 687-691.
16. Anonymous. Indian Pharmacopoeia. Vol. 1-2. New Delhi: The Controller of Publication, Govt. of India, Ministry of Health and Family Welfare; 2007.
17. Vazir A, Divakar G. Development and characterization of in situ gel of xanthan gum for ophthalmic formulation containing brimonidine tartrate. Asian J Pharm Clin Res 2015, 8(1):37:41
18. Mathews B. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 1999;25:831-856.
19. Suma P, Jayant S, Srinivas M, Bhabani S, Chaudhari P, Sharada R, Nayanabhirama U, Bola S. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin. Nanoscale 2017:9:10919-10932.